Koers ASKA Pharmaceutical Co., Ltd. Japan Exchange
Aandelen
4514
JP3541200006
Farmaceutische producten
Omzet 2024 | 62,84 mld. 406 mln. 373 mln. | Omzet 2025 * | 64,48 mld. 416 mln. 382 mln. | Marktkapitalisatie | 66,32 mld. 428 mln. 393 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 | 7,54 mld. 48,69 mln. 44,74 mln. | Nettowinst (verlies) 2025 * | 5,11 mld. 32,98 mln. 30,31 mln. | EV/omzet 2024 | 1 x |
Nettoliquiditeiten 2024 * | 16,35 mld. 106 mln. 96,96 mln. | Nettoliquiditeiten 2025 * | 12,31 mld. 79,42 mln. 72,99 mln. | EV/omzet 2025 * | 0,84 x |
K/w-verhouding 2024 |
8,33
x | K/w-verhouding 2025 * |
13
x | Werknemers | 747 |
Dividendrendement 2024 |
1,8% | Dividendrendement 2025 * |
2,14% | Vrij verhandelbaar | 0% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
President | 72 | 01-04-21 | |
Kiyohiko Tamura
ADM | Chief Administrative Officer | - | - |
Kunihiro Gunji
CMP | Compliance Officer | - | 01-04-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
President | 72 | 01-04-21 | |
Atsushi Maruo
BRD | Director/Board Member | 65 | 01-04-21 |
Director/Board Member | 75 | 01-04-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+31,37% | 588 mld. | |
-2,56% | 364 mld. | |
+20,79% | 326 mld. | |
+5,89% | 285 mld. | |
+14,83% | 239 mld. | |
+9,93% | 210 mld. | |
-6,95% | 200 mld. | |
+11,17% | 167 mld. | |
+0,07% | 161 mld. |